Fraunhofer Institute of Translational Medicine and Pharmacology ITMP, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany; Fraunhofer Cluster of Excellence for Immune-Mediated Diseases CIMD, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany; Institute of Clinical Pharmacology, Faculty of Medicine, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany.
Fraunhofer Institute of Translational Medicine and Pharmacology ITMP, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany; Institute of Biochemistry II, Faculty of Medicine, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany; Buchmann Institute for Molecular Life Sciences, Goethe University Frankfurt, Max-von-Laue-Straße 15, 60438 Frankfurt am Main, Germany; Department of Theoretical Biophysics, Max Planck Institute of Biophysics, Max-von-Laue Straße 3, 60438 Frankfurt am Main, Germany.
Cell Chem Biol. 2021 Jul 15;28(7):1014-1031. doi: 10.1016/j.chembiol.2021.04.007. Epub 2021 May 3.
Efficacy and selectivity of molecules inducing protein degradation depend on their affinity to the target protein but also on the type of E3 ubiquitin ligase that is recruited to trigger proteasomal degradation. While tremendous progress has been made on the former, the latter-the arsenal of E3 ligases that can be hijacked for targeted protein degradation-is still largely unexplored. Only about 2% of the more than 600 E3 ligases have been utilized to date. Exploiting additional E3 ligases that are, for example, selectively expressed in specific tissues or cells, or regulated under certain conditions, can considerably broaden the applicability of molecular degraders as a therapeutic modality. Here, we provide an overview of major classes of E3 ligases, review the enzymes that have been exploited for induced protein degradation and approaches used to identify or design E3 ligands, and highlight challenges and opportunities for targeting new E3 ligases.
分子诱导蛋白质降解的功效和选择性不仅取决于它们与靶蛋白的亲和力,还取决于招募来触发蛋白酶体降解的 E3 泛素连接酶的类型。虽然在前一种方法上已经取得了巨大进展,但后一种方法——可用于靶向蛋白质降解的 E3 连接酶库——在很大程度上仍未被探索。迄今为止,仅利用了超过 600 种 E3 连接酶中的约 2%。利用其他 E3 连接酶,例如选择性表达在特定组织或细胞中或在特定条件下受到调节的 E3 连接酶,可以大大拓宽分子降解剂作为治疗方式的适用性。在这里,我们提供了 E3 连接酶主要类别的概述,回顾了已被用于诱导蛋白质降解的酶以及用于鉴定或设计 E3 配体的方法,并强调了针对新 E3 连接酶的挑战和机遇。